← Back to Search

Stress Kinase Inhibitor

MW150 for Alzheimer's Disease (SKI-AD Trial)

Phase 2
Waitlist Available
Led By Lawrence S Honig, MD PhD
Research Sponsored by Neurokine Therapeutics
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Male or female, age 50 to 90 inclusive
Meet criteria for Alzheimer's Disease by NIAA-AA criteria
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 84 days treatment
Awards & highlights

SKI-AD Trial Summary

This trial is testing a new drug for Alzheimer's disease. The goals are to see if it is safe and if it improves cognition, daily living, and behavior.

Who is the study for?
This trial is for men and women aged 50-90 with mild-to-moderate Alzheimer's Disease, who have a study partner and can speak English fluently. Participants must not have significant other medical conditions or psychiatric disorders, no recent drug/alcohol abuse, and if female, be non-childbearing. Males must agree to use contraception.Check my eligibility
What is being tested?
The trial tests MW150, an oral drug believed to affect stress kinases involved in Alzheimer's. It compares the effects of MW150 against a placebo on safety, how the body processes it, cognitive performance, daily activities behavior and blood biomarkers.See study design
What are the potential side effects?
Specific side effects are not listed but will include monitoring for any adverse reactions related to the investigational drug MW150 as compared to a placebo. Safety assessments will focus on tolerability and potential impacts on liver function.

SKI-AD Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am between 50 and 90 years old.
Select...
I have been diagnosed with Alzheimer's Disease.
Select...
I have someone who can come with me to appointments and sees me often.
Select...
I am a woman who cannot become pregnant because I am postmenopausal or have been surgically sterilized.
Select...
I can hear and see well enough for daily activities.

SKI-AD Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~84 days treatment
This trial's timeline: 3 weeks for screening, Varies for treatment, and 84 days treatment for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Drug Safety- Blood tests
Drug Safety- C-SSRS
Drug Safety- Electrocardiographic
+1 more
Secondary outcome measures
Behavioral Scale - NPI-Q
Cognitive change-ADAScog
Cognitive change-Executive
+6 more

SKI-AD Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: 10mg MW150 dailyExperimental Treatment1 Intervention
10 mg MW150 daily (1 capsule of 10 mg daily)
Group II: placebo dailyPlacebo Group1 Intervention
placebo daily (1 capsule of matched placebo daily)

Find a Location

Who is running the clinical trial?

Neurokine TherapeuticsLead Sponsor
Columbia UniversityOTHER
1,424 Previous Clinical Trials
2,473,003 Total Patients Enrolled
National Institute on Aging (NIA)NIH
1,655 Previous Clinical Trials
28,004,146 Total Patients Enrolled

Media Library

MW150 (Stress Kinase Inhibitor) Clinical Trial Eligibility Overview. Trial Name: NCT05194163 — Phase 2
Alzheimer's Disease Research Study Groups: 10mg MW150 daily, placebo daily
Alzheimer's Disease Clinical Trial 2023: MW150 Highlights & Side Effects. Trial Name: NCT05194163 — Phase 2
MW150 (Stress Kinase Inhibitor) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05194163 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What results are researchers expecting to gain from this experiment?

"This 84-day trial is designed to evaluate the safety of a certain drug, with cognitive changes assessed using the Alzheimer's disease Assessment Scale (ADAScog), MiniMental State Examination (MMSE) and Trails A/B tests."

Answered by AI

Are there any openings for participation in this clinical trial?

"Per the clinicaltrials.gov database, this study is not presently in search of participants. Initially posted on May 1st 2022 and last updated a few months ago on March 13th 2022, there are 546 other trials currently taking new members."

Answered by AI

What risks are associated with the use of MW150 for patient care?

"Our team at Power has evaluated MW150's safety, assigning it a score of 2 due to the fact that Phase 2 trials have only yielded data pertaining to its safety and not efficacy."

Answered by AI

Are individuals of a younger age eligible for this exploration?

"As specified in the trial's eligibility requirements, participants must be between 50 and 90 years old."

Answered by AI

Is there a certain demographic that is recommended to be involved in this clinical exploration?

"This clinical research is searching for 24 volunteers aged between 50 and 90 years old who have been diagnosed with Alzheimer's disease. In addition, potential participants must be able to provide informed consent (or through a legally authorized representative), their gender must match the criteria set out by NIAA-AA guidelines, they need to possess fluency in English, at least 8 years of schooling, functioning auditory and visual abilities; an MMSE score ranging from 14 to 28 and a CDR Global Score of 0.5 - 2.0 while having no suicidal thoughts or attempts within the past 12 months."

Answered by AI
~4 spots leftby Aug 2024